Fox Run Management L.L.C. Takes Position in Urogen Pharma $URGN

Key Points

• Fox Run Management L.L.C. has acquired a new stake in Urogen Pharma, purchasing 36,271 shares valued at approximately $401,000, establishing ownership of 0.08% of the company.
• Despite a negative earnings report with a loss of ($1.05) per share, Urogen Pharma's stock has garnered several "buy" ratings from analysts, with an average target price of $31.43.
• Insider activity is notable as Mark Schoenberg sold 10,000 shares at an average price of $17.69, which reduced his ownership by 6.32%, and multiple insiders have sold 27,833 shares in the last 90 days.

Fox Run Management L.L.C. purchased a new position in Urogen Pharma (NASDAQ:URGN - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 36,271 shares of the company's stock, valued at approximately $401,000. Fox Run Management L.L.C. owned about 0.08% of Urogen Pharma at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. CWM LLC raised its holdings in shares of Urogen Pharma by 6,047.1% in the 1st quarter. CWM LLC now owns 5,225 shares of the company's stock worth $58,000 after purchasing an additional 5,140 shares during the period. Lazard Asset Management LLC purchased a new position in shares of Urogen Pharma in the 4th quarter worth about $67,000. GAMMA Investing LLC raised its holdings in shares of Urogen Pharma by 6,908.4% in the 1st quarter. GAMMA Investing LLC now owns 7,499 shares of the company's stock worth $83,000 after purchasing an additional 7,392 shares during the period. Aquatic Capital Management LLC purchased a new position in shares of Urogen Pharma in the 4th quarter worth about $101,000. Finally, ProShare Advisors LLC purchased a new position in shares of Urogen Pharma in the 4th quarter worth about $137,000. 91.29% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Urogen Pharma

In related news, insider Mark Schoenberg sold 10,000 shares of the business's stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $17.69, for a total transaction of $176,900.00. Following the completion of the transaction, the insider owned 148,229 shares in the company, valued at $2,622,171.01. The trade was a 6.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, General Counsel Jason Drew Smith sold 7,522 shares of the business's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $19.14, for a total value of $143,971.08. Following the transaction, the general counsel owned 41,492 shares of the company's stock, valued at $794,156.88. This represents a 15.35% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 27,833 shares of company stock valued at $457,467. Insiders own 4.70% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Piper Sandler started coverage on Urogen Pharma in a report on Monday. They issued an "overweight" rating and a $36.00 price objective on the stock. The Goldman Sachs Group set a $16.00 target price on Urogen Pharma and gave the company a "neutral" rating in a report on Friday, June 13th. Guggenheim reiterated a "buy" rating and set a $30.00 target price (up from $15.00) on shares of Urogen Pharma in a report on Friday, June 13th. Oppenheimer set a $31.00 target price on Urogen Pharma and gave the company a "buy" rating in a report on Friday, June 13th. Finally, D. Boral Capital reiterated a "buy" rating and set a $25.00 target price on shares of Urogen Pharma in a report on Tuesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, Urogen Pharma presently has an average rating of "Buy" and an average price target of $32.00.

Urogen Pharma Stock Up 2.4%

Shares of URGN traded up $0.47 during mid-day trading on Thursday, hitting $19.78. The stock had a trading volume of 728,635 shares, compared to its average volume of 1,077,608. The company has a market cap of $915.02 million, a PE ratio of -5.96 and a beta of 1.12. The company's fifty day simple moving average is $16.35 and its two-hundred day simple moving average is $11.88. Urogen Pharma has a fifty-two week low of $3.42 and a fifty-two week high of $21.01.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.23). The firm had revenue of $24.22 million during the quarter, compared to analyst estimates of $23.06 million. Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 164.44%. Equities analysts expect that Urogen Pharma will post -3.12 earnings per share for the current year.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.